News

Everyday Health on MSN10h
Zebound Beats Wegovy for Weight Loss in First Head-to-Head Trial
In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Health Rounds: Study suggests lower Wegovy dose might be just as effective
Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...
TAG24 on MSN10m
Study: Wegovy cuts heart disease risk even before people shed weight
The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...
Zacks Investment Research on MSN18h
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
Investing Snacks17h
Big Pharma, Bigger Flex: Lilly’s $1,100 Target
Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.